YuliaRozenMD

PubMed

• Survival of enteric bacteria in seawater.
  Rozen, Y., Belkin, S.> ;FEMS Microbiol Rev. 2001 Dec
• Improved method for the quality assurance of [C-11]choline.
  Mishani, E., Ben-David, I., Rozen, Y.> ;Nucl Med Biol. 2002 Apr
• Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase.
  Bonasera, T. A., Ortu, G., Rozen, Y., Krais, R., Freedman, N. M., Chisin, R., Gazit, A., Levitzki, A., Mishani, E.> ;Nucl Med Biol. 2001 May
• High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent...
  Mishani, E., Abourbeh, G., Jacobson, O., Dissoki, S., Ben Daniel, R., Rozen, Y., Shaul, M., Levitzki, A.> ;J Med Chem. 2005 Aug 11
• Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer.
  Shaul, M., Abourbeh, G., Jacobson, O., Rozen, Y., Laky, D., Levitzki, A., Mishani, E.> ;Bioorg Med Chem. 2004 Jul 1
• Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors.
  Mishani, E., Abourbeh, G., Rozen, Y., Jacobson, O., Laky, D., Ben David, I., Levitzki, A., Shaul, M.> ;Nucl Med Biol. 2004 May
• Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride.
  Ben-David, I., Rozen, Y., Ortu, G., Mishani, E.> ;Appl Radiat Isot. 2003 Feb
• Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.
  Ortu, G., Ben-David, I., Rozen, Y., Freedman, N. M., Chisin, R., Levitzki, A., Mishani, E.> ;Int J Cancer. 2002 Oct 1
• Join now to see all